Novo’s QW Insulin Icodec Meets Primary Endpoint in ONWARDS 5

Novo Nordisk announced positive topline results from the final QW insulin icodec Ph3 trial (ONWARDS 5). Recall, ONWARDS 5 is differentiated from the other five trials in the ONWARDS program as it uses the DoseGuide app for titration. Below, FENIX provides thoughts on Novo’s Ph3 ONWARDS icodec program, the utility of the DoseGuide app during icodec commercialization, and the potential regulatory timeline.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.